Clinical Usefulness of Long-term Application of Fentanyl Matrix in Chronic Non-Cancer Pain: Improvement of Pain and Physical and Emotional Functions.
10.4055/cios.2016.8.4.465
- Author:
Jaewon LEE
1
;
Joon Shik YOON
;
Jae Hyup LEE
;
So Hak CHUNG
;
Kyu Yeol LEE
;
Young Yul KIM
;
Jong Moon KIM
;
Min Ho KONG
;
Ung Gu KANG
;
Ye Soo PARK
Author Information
1. Department of Orthopedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri, Korea. hyparkys@hanyang.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Chronic non-cancer pain;
Fentanyl matrix;
Physical functioning;
Emotional functioning
- MeSH:
Acetaminophen;
Activities of Daily Living;
Analgesics, Opioid;
Chronic Pain;
Dizziness;
Fentanyl*;
Health Surveys;
Humans;
Incidence;
Korea;
Nausea;
Observational Study;
Prospective Studies;
Pruritus;
Research Personnel;
Vomiting
- From:Clinics in Orthopedic Surgery
2016;8(4):465-474
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. METHODS: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 µg/hr, 25 µg/hr, or 50 µg/hr depending on the patient's response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. RESULTS: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. CONCLUSIONS: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.
